Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Cilloni

Showing results (131-140 of 193) with videos related to

Pageof 20
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatmentIlaria Iacobucci, Gianantonio Rosti, Marilina Amabile, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CMLFrancesca Palandri, Ilaria Iacobucci, Giovanni Martinelli, et al.
International Journal of Molecular Sciences|October 21, 2020
Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic CellsChiara Calabrese, Cristina Panuzzo, Serena Stanga, et al.
Blood|December 3, 2003
Molecular response to imatinib in late chronic-phase chronic myeloid leukemiaGianantonio Rosti, Giovanni Martinelli, Simona Bassi, et al.
British Journal of Haematology|November 16, 2011
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)Sergio Amadori, Roberto Stasi, Alberto M Martelli, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 22, 2015
Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemiaStefania Trino, Luciana De Luca, Vittorio Simeon, et al.
American Journal of Hematology|June 7, 2016
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patientsPaola Guglielmelli, Giada Rotunno, Annalisa Pacilli, et al.
Haematologica|August 2, 2007
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective studyMichele Baccarani, Daniela Cilloni, Michela Rondoni, et al.
Cellular Oncology (Dordrecht, Netherlands)|July 20, 2017
EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cellsFrancesco La Rocca, Irma Airoldi, Emma Di Carlo, et al.
Blood|August 21, 2004
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemiaMichele Baccarani, Giovanni Martinelli, Gianantonio Rosti, et al.
Pageof 20

Showing results (131-140 of 193) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatmentIlaria Iacobucci, Gianantonio Rosti, Marilina Amabile, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CMLFrancesca Palandri, Ilaria Iacobucci, Giovanni Martinelli, et al.
International Journal of Molecular Sciences|October 21, 2020
Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic CellsChiara Calabrese, Cristina Panuzzo, Serena Stanga, et al.
Blood|December 3, 2003
Molecular response to imatinib in late chronic-phase chronic myeloid leukemiaGianantonio Rosti, Giovanni Martinelli, Simona Bassi, et al.
British Journal of Haematology|November 16, 2011
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)Sergio Amadori, Roberto Stasi, Alberto M Martelli, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 22, 2015
Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemiaStefania Trino, Luciana De Luca, Vittorio Simeon, et al.
American Journal of Hematology|June 7, 2016
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patientsPaola Guglielmelli, Giada Rotunno, Annalisa Pacilli, et al.
Haematologica|August 2, 2007
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective studyMichele Baccarani, Daniela Cilloni, Michela Rondoni, et al.
Cellular Oncology (Dordrecht, Netherlands)|July 20, 2017
EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cellsFrancesco La Rocca, Irma Airoldi, Emma Di Carlo, et al.
Blood|August 21, 2004
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemiaMichele Baccarani, Giovanni Martinelli, Gianantonio Rosti, et al.
Pageof 20